Cargando…

Drugs repurposing against SARS-CoV2 and the new variant B.1.1.7 (alpha strain) targeting the spike protein: molecular docking and simulation studies

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is responsible for the global COVID-19 pandemic and millions of deaths worldwide. In December 2020, a new alpha strain of SARS-CoV2 was identified in the United Kingdom. It was referred to as VUI 202012/01 (Alpha strain modelled under inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pande, Monu, Kundu, Debanjan, Srivastava, Ragini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367657/ https://www.ncbi.nlm.nih.gov/pubmed/34423145 http://dx.doi.org/10.1016/j.heliyon.2021.e07803

Ejemplares similares

Functional evaluation of the P681H mutation on the proteolytic activation the SARS-CoV-2 variant B.1.1.7 (Alpha) spike
por: Lubinski, Bailey, et al.
Publicado: (2021)

Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike
por: Lubinski, Bailey, et al.
Publicado: (2021)

Tracking of SARS-CoV-2 Alpha variant (B.1.1.7) in Palestine
por: Nasereddin, Abedelmajeed, et al.
Publicado: (2022)

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
por: Meng, Bo, et al.
Publicado: (2021)

Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
por: van Ogtrop, M. L., et al.
Publicado: (2021)

Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein
por: Borocci, Stefano, et al.
Publicado: (2021)

Impact of SARS-CoV-2 Alpha variant (B.1.1.7) on prisons, England
por: Vusirikala, Amoolya, et al.
Publicado: (2022)

Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma) variant spike glycoproteins: A computational approach
por: Yele, Vidyasrilekha., et al.
Publicado: (2021)

B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark
por: Michaelsen, Thomas Y., et al.
Publicado: (2022)

The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico
por: Zárate, Selene, et al.
Publicado: (2022)

UK B.1.1.7 (Alpha) variant exhibits increased respiratory replication and shedding in nonhuman primates
por: Rosenke, Kyle, et al.
Publicado: (2021)

Emergence and spread of a sub-lineage of SARS-CoV-2 Alpha variant B.1.1.7 in Europe, and with further evolution of spike mutation accumulations shared with the Beta and Gamma variants
por: Stadtmüller, Marlena, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2
por: Port, Julia, et al.
Publicado: (2021)

Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2
por: Port, Julia R., et al.
Publicado: (2021)

Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach
por: Carcereny, Albert, et al.
Publicado: (2022)

Epidemiological and molecular description of nosocomial outbreak of COVID-19 Alpha (B.1.1.7) variant in Saudi Arabia
por: Alsaedi, Asim, et al.
Publicado: (2022)

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
por: Graham, Carl, et al.
Publicado: (2021)

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
por: Xia, Shuai, et al.
Publicado: (2021)

First Report of SARS-CoV-2 Lineage B.1.1.7 (Alpha Variant) in Ecuador, January 2021
por: Carrazco-Montalvo, Andres, et al.
Publicado: (2021)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents
por: Gurevich, Michael, et al.
Publicado: (2022)

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

The incubation period of the SARS-CoV-2 B1.1.7 variant is shorter than that of other strains
por: Homma, Yoshito, et al.
Publicado: (2021)

Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations
por: Lazniewski, Michal, et al.
Publicado: (2022)

Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants
por: Trobajo-Sanmartín, Camino, et al.
Publicado: (2022)

Structural modelling of SARS-CoV-2 alpha variant (B.1.1.7) suggests enhanced furin binding and infectivity
por: Mohammad, Anwar, et al.
Publicado: (2021)

First detection of an Italian human-to-cat outbreak of SARS-CoV-2 Alpha variant – lineage B.1.1.7
por: Zoccola, Roberto, et al.
Publicado: (2021)

Anthropogenic Infection of Domestic Cats With SARS-CoV-2 Alpha Variant B.1.1.7 Lineage in Buenos Aires
por: Pecora, Andrea, et al.
Publicado: (2022)

Vaccine Effectiveness during Outbreak of COVID-19 Alpha (B.1.1.7) Variant in Men’s Correctional Facility, United States
por: Silverman, Rachel A., et al.
Publicado: (2022)

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
por: Graham, Carl, et al.
Publicado: (2021)

Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach
por: Pulakuntla, Swetha, et al.
Publicado: (2021)

Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England
por: Grint, Daniel J, et al.
Publicado: (2021)

Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections
por: Parker, Matthew D., et al.
Publicado: (2022)

Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study
por: Eweas, Ahmad F., et al.
Publicado: (2022)

Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7
por: Peters, Michael H., et al.
Publicado: (2021)

COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2
por: Kumar, Nitya, et al.
Publicado: (2022)

Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual
por: Kernéis, Solen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5o1s07m00g4flmumep1iihgpg0